Monographie - Folinate calcium

Última actualización :
19/11/2024

Folinate calcium

Factores que influyen sobre la estabilidad

Estructura química

Nombre comercial

Los nombres comerciales son orientativos y los excipientes de la formulación pueden ser distintos dependiendo del país y del laboratorio fabricante.

Antrex	Finlandia
Axifolin	Alemania
Bendafolin	Egipto, Irán
Biofolic	Italia
Calcium leucovorin	Turquía
Calfolex	Italia
Citofolin	Italia
Cromaton	Luxemburgo
Dalisol	Colombia, India, México
Degalin	Alemania
Durofolin	Grecia
Etamolin	Marruecos
Eurofolic	Alemania
Fastovorin	India
Folcasin	Rumania
Folical	Colombia
Folidan	España
Folinate de calcium	Francia
Furoic	Italia
Innefol	México
Lederfolin	Gran Bretaña, Irlanda, Italia
Ledervorin calcium	Arabia Saudita, Australia, Bélgica, Colombia, Emiratos Árabes Unidos, Irlanda, Luxemburgo, Polonia
Leucocalcin	Argentina, Chile
Leucovorin	Alemania, Austria, Bélgica, Eslovenia, Gran Bretaña, Grecia, Hungría, Polonia, Suiza, Turquía
Neofolin	Alemania
Novizet	Argentina
Precileucin	México
Prefolic	Italia
Refolinon	Gran Bretaña, Grecia
Rescuvolin	Alemania, Bélgica, Colombia, Grecia, Luxemburgo, Malasia, Países Bajos, Sudafrica, Suecia
Ribofolin	Alemania, Austria, Irán
Rontafor	Argentina
Sanficinate	Grecia
Sanifolin	Italia
Tecnovorin	Colombia, Marruecos
Veravorin	Grecia
Xanacanto	México

Bibliografía : Folinate calcium

	Tipo	Publicación
73	periódico	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	periódico	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
99	periódico	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
150	periódico	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
155	periódico	Trissel LA, Martinez JF, Xu QA. Incompatibility of fluorouracil with leucovorin calcium or levoleucovorin calcium. Am J Health-Syst Pharm 1995 ; 52: 710-715.
182	periódico	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	periódico	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	periódico	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	periódico	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
301	periódico	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
479	periódico	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
496	periódico	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
763	periódico	Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH. Drug precipitation within IV tubing : A potential hazard of chemotherapy administration. Cancer Treat Rep 1985 ; 69: 1325-1326.
905	periódico	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	periódico	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1287	periódico	Lecompte D, Bousselet M, Gayrard D, Poitou P. Stability study of reconstituted and diluted solutions of calcium folinate. Pharm Ind 1991 ; 53: 90-94.
1410	periódico	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	periódico	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	periódico	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	periódico	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1625	periódico	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	periódico	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1754	periódico	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1914	Laboratorio	Pemetrexed (Alimta®) - Summary of Product Characteristics Eli Lilly 2016
1925	periódico	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	periódico	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	periódico	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2027	periódico	Walker SE, Shirley L, Puodziunas A. Simulation of Y-site compatibility of irinotecan and leucovorin at room temperature in 5% dextrose in water in 3 different containers. Can J Hosp Pharm 2005 ; 58: 212-222.
2130	periódico	Lokiec F, Amirault P, Bonnans H, Gauzan MF, Sauvage N, Santoni J. Stabilité du mélange 5-fluoro-uracil-acide fonique : influence des concentrations, du contenant et de la forme de l’acide folinique. Bull Cancer 1999 ; 86, 11: 946-954.
2181	periódico	Milano G, Renée N. Etude de compatibilité physicochimique 5- fluoro-uracile (nouvelle préparation française) - acide folinique. Bull Cancer 1995 ; 82: 189-195.
2295	Laboratorio	Fosaprepitant (Emend®) - Summary of Product Characteristics Merck Sharp Dohme 2013
2340	periódico	Walker S.E, Law S, Puodziunas A. Simulation of Y-Site Compatibility of Irinotecan and Leucovorin at Room Temperature in 5% Dextrose in Water in 3 Different Containers Can J Hosp Pharm 2005 ; 58, 4: 212-222.
3474	Laboratorio	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3523	Laboratorio	Ceftriaxone (Rocephin®) - Summary of Product Characteristics. Roche 2018
3546	Laboratorio	Cefamandole Flavelab - Résumé des caractéristiques du produit Panpharma SA 2007
3619	Laboratorio	Pamidronate (Pamidronate Actavis®) - Summary of Product Characteristics Wockhardt 2016
3621	Laboratorio	Phosphate dipotassique - Résumé des caractéristiques du produit Renaudin 2008
3634	Laboratorio	Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit Accord Healthcare 2011
3694	periódico	Smith J.A, Morris A, Duafala M.E, Bertino J.R, Markman M, Kleinberg M. Stability of floxuridine and leucovorin calcium admixtures for intraperitoneal administration. Am J Hosp Pharm 1989 ; 46: 985-989.
3753	Laboratorio	Tedizolid phosphate (Sivextro®) - Summary of Product Characteristics Cubist Pharmaceuticals 2014
3838	Laboratorio	Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
3933	Laboratorio	Acide zolédronique - (Acide zoledronique Teva Pharma) - Résumé des caractéristiques du produit Teva Laboratoire 2015
4154	Laboratorio	Bleomycin sulfate- Summary of Product Characteristics Accord Health Care 2018
4720	Laboratorio	Nuzyra (amadacycline - Full prescribing infomation. Paratek Pharmaceuticals updated May 2021. Paratek Pharmaceuticals 2021

Mentions Légales